Literature DB >> 24621430

The dosimetric effects of photon energy on the quality of prostate volumetric modulated arc therapy.

Malcolm D Mattes1, Cyril Tai2, Alvin Lee2, Hani Ashamalla2, N C Ikoro2.   

Abstract

PURPOSE: Studies comparing the dosimetric effects of high- and low-energy photons to treat prostate cancer using 3-dimensional conformal and intensity modulated radiation therapy have yielded mixed results. With the advent of newer radiation delivery systems like volumetric modulated arc therapy (VMAT), the impact of changing photon energy is readdressed. METHODS AND MATERIALS: Sixty-five patients treated for prostate cancer at our institution from 2011 to 2012 underwent CT simulation. A target volume encompassing the prostate and entire seminal vesicles was treated to 50.4 Gy, followed by a boost to the prostate and proximal seminal vesicles to a total dose of 81 Gy. The VMAT plans were generated for 6-MV and 10-MV photons under identical optimization conditions using the Eclipse system version 8.6 (Varian Medical Systems, Palo Alto, CA). The analytical anisotropic algorithm was used for all dose calculations. Plans were normalized such that 98% of the planning target volume (PTV) received 100% of the prescribed dose. Dose-volumetric data from the treatment planning system was recorded for both 6-MV and 10-MV plans, which were compared for both the entire cohort and subsets of patients stratified according to the anterior-posterior separation.
RESULTS: Plans using 10-MV photons had statistically significantly lower relative integral dose (4.1%), gradient measure (4.1%), skin Dmax (16.9%), monitor units (13.0%), and bladder V(30) (3.1%) than plans using 6-MV photons (P < .05). There was no difference in rectal dose, high-dose-region bladder dose, PTV coverage, or conformity index. The benefit of 10-MV photons was more pronounced for thicker patients (anterior-posterior separation >21 cm) for most parameters, with statistically significant differences in bladder V(30), bladder V(65), integral dose, conformity index, and monitor units.
CONCLUSIONS: The main dosimetric benefits of 10-MV as compared with 6-MV photons are seen in thicker patients, though for the entire cohort 10-MV plans resulted in a lower integral dose, gradient measure, skin Dmax, monitor units, and bladder V(30), possibly at the expense of higher rectum V(81).
Copyright © 2014 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24621430     DOI: 10.1016/j.prro.2013.03.001

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  5 in total

1.  Dosimetric influence of photon beam energy and number of arcs on volumetric modulated arc therapy in carcinoma cervix: A planning study.

Authors:  Girigesh Yadav; Manindra Bhushan; Abhinav Dewan; Upasna Saxena; Lalit Kumar; Deepika Chauhan; Kothanda Raman; Swarupa Mitra; Mahammood Suhail
Journal:  Rep Pract Oncol Radiother       Date:  2016-10-17

2.  The dosimetric impact of different photon beam energy on RapidArc radiotherapy planning for cervix carcinoma.

Authors:  Lalit Kumar; Girigesh Yadav; Kothanda Raman; Manindra Bhushan; Manoj Pal
Journal:  J Med Phys       Date:  2015 Oct-Dec

3.  The dosimetric significance of using 10 MV photons for volumetric modulated arc therapy for post-prostatectomy irradiation of the prostate bed.

Authors:  Henry Kleiner; Matthew B Podgorsak
Journal:  Radiol Oncol       Date:  2016-02-22       Impact factor: 2.991

4.  Evaluation of mixed energy partial arcs for volumetric modulated arc therapy for prostate cancer.

Authors:  Shadab Momin; James L Gräfe; Rao F Khan
Journal:  J Appl Clin Med Phys       Date:  2019-03-12       Impact factor: 2.102

5.  Impact of nominal photon energies on normal tissue sparing in knowledge-based radiotherapy treatment planning for rectal cancer patients.

Authors:  Yuliang Huang; Sha Li; Haizhen Yue; Meijiao Wang; Qiaoqiao Hu; Haiyang Wang; Tian Li; Chenguang Li; Hao Wu; Yibao Zhang
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.